Proactive Monitoring and Red Flags
At a Glance
APDS2 needs an individualized monitoring and fever plan because chronic lung disease, serious infections, and lymphoma can develop quietly. Seek prompt care for changing lymph nodes, unexplained fever, night sweats, weight loss, persistent gut symptoms, breathing trouble, or bleeding.
Living with APDS2 requires a shift from reactive care (treating problems as they arise) to proactive surveillance. Because the disease is rare and its risks—such as lung damage and lymphoma—can develop silently, an individualized monitoring plan guided by your symptoms is the most powerful tool you have to protect long-term health [1][2].
Long-Term Outlook and Risks
While APDS2 is a serious condition, understanding the risks allows for better preparation.
- Leading Risks: The most significant long-term concerns are chronic lung infections and B-cell lymphoma, a type of blood cancer [3][4]. Across large groups of patients, lymphoma and infection are the most common causes of mortality [3].
- Historical Survival Data: Pooled historical data for APDS (combining types 1 and 2) show a survival rate of approximately 87% at age 20 and 74% at age 30 [5]. It is crucial to understand that these are historical, pooled population estimates, not a personal prognosis. Individual outcomes vary significantly based on how early the disease is caught and managed, and these figures may not reflect outcomes with current targeted treatments [6][7].
- Lung Health: A subset of patients develop bronchiectasis (permanent airway scarring), making lung monitoring a lifelong priority [4][8].
Recommended Surveillance Strategy
There is no “one-size-fits-all” calendar or universally validated lymphoma-screening protocol for every APDS2 patient. Your doctor will adjust these based on your specific history [1].
| Area of Concern | Monitoring Tool | Typical Approach |
|---|---|---|
| Lungs | Pulmonary Function Tests (PFTs) & symptom review. | Routine clinical assessment [2]. |
| High-Resolution CT Scan of the chest. | When clinically indicated (avoiding routine radiation) [8]. | |
| Lymphoma | Physical exam of lymph nodes and spleen. | Regular clinical examination [2]. |
| Complete Blood Count (CBC) and EBV viral load. | Individualized (e.g., EBV testing is relevant in specific clinical settings) [2][9]. | |
| FDG-PET/CT or MRI. | Only if malignancy is suspected [10]. | |
| Growth/Gut | Growth charts and BMI tracking. | Routine checks in children [4]. |
| Gastrointestinal review (diarrhea/pain). | Discussed at routine visits [11]. |
Managing “Scanxiety”
It is normal to feel significant anxiety before scheduled scans or lab tests. Remember that the goal of these tests is to evaluate issues while they are manageable. If a scan shows “stable” findings—even if those findings (like enlarged nodes) are not “normal”—that is often reassuring relative to growth, though stability alone does not replace clinical examination and context [10].
Red Flags and Fever Plan: When to Seek Medical Care
In APDS2, you need a clear, clinician-directed fever and infection action plan. Do not wait for listed signs of sepsis (like confusion or mottled skin) to seek care. A new fever or suspected infection may require same-day or emergency assessment depending on your immune profile. Ask your immunologist for an individualized temperature threshold and an after-hours contact plan.
Routine Monitoring (Mention at next visit)
- Stable, painless, small swollen glands during a common cold.
- Mild, familiar fatigue.
- Occasional loose stools that resolve quickly.
Same-Day Call (Contact your immunologist today)
- Rapid Change: A lymph node that is growing quickly or becomes painful [12].
- B-Symptoms: Unexplained fevers, drenching night sweats, or unintentional weight loss [9].
- New Asymmetry: One side of the neck or armpit is significantly more swollen than the other [12].
- Persistent Gut Issues: Chronic diarrhea, severe abdominal pain, or blood in the stool [13][9].
Emergency (Call 911 or go to the ER immediately)
- Respiratory Distress: Difficulty breathing, blue tint to the lips, or using chest muscles to “pull” in air [14].
- Severe Infection/Sepsis: High fever reaching your personalized threshold, inability to keep fluids down, extreme shivering, or lethargy [14][15].
- Acute Bleeding: Coughing up blood (hemoptysis) or severe gastrointestinal bleeding [16].
- Severe Pain: Sudden, agonizing abdominal pain which could indicate a bowel issue called intussusception [13].
Early intervention during these red-flag events is the most effective way to prevent serious complications [1]. Always trust your intuition as a patient or caregiver—if something feels fundamentally different than your usual symptoms, seek care [7].
Common questions in this guide
How often does someone with APDS2 need lung monitoring?
How is lymphoma risk monitored in APDS2?
What APDS2 symptoms should prompt a same-day call?
When should an APDS2 fever be treated as an emergency?
What does a stable scan mean in APDS2?
Can APDS2 cause bronchiectasis?
What is the long-term outlook for people with APDS2?
Get notified when new evidence is published on immunodeficiency 132b.
We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.
References
References (16)
- 1
Spanish Consensus on the Diagnosis and Management of Patients With Activated PI3K Delta Syndrome (APDS).
Neth O, Alsina L, Rivière JG, et al.
Journal of investigational allergology & clinical immunology 2025; (35(2)):87-102 doi:10.18176/jiaci.1059.
PMID: 40028901 - 2
Key outcomes in treatment of activated phosphoinositide 3-kinase delta syndrome: An e-Delphi panel study and responder threshold application.
Upton JEM, Williams KW, Cant A, et al.
PloS one 2025; (20(10)):e0333341 doi:10.1371/journal.pone.0333341.
PMID: 41091701 - 3
Genetic Etiologies and Outcomes in Malignancy and Mortality in Activated Phosphoinositide 3-Kinase Delta Syndrome: A Systematic Review.
Büsch K, Memmott HL, McLaughlin HM, et al.
Advances in therapy 2025; (42(2)):752-771 doi:10.1007/s12325-024-03066-7.
PMID: 39636570 - 4
Clinical and immunologic phenotype associated with activated phosphoinositide 3-kinase δ syndrome 2: A cohort study.
Elkaim E, Neven B, Bruneau J, et al.
The Journal of allergy and clinical immunology 2016; (138(1)):210-218.e9 doi:10.1016/j.jaci.2016.03.022.
PMID: 27221134 - 5
Systematic review of mortality and survival rates for APDS.
Hanson J, Bonnen PE
Clinical and experimental medicine 2024; (24(1)):17 doi:10.1007/s10238-023-01259-y.
PMID: 38280023 - 6
Overall survival among patients with activated phosphoinositide 3-kinase delta syndrome (APDS).
Mahendran M, Upton JEM, Ramasubramanian R, et al.
Orphanet journal of rare diseases 2025; (20(1)):212 doi:10.1186/s13023-025-03734-z.
PMID: 40319290 - 7
Activated phosphoinositide 3-kinase δ syndrome: Update from the ESID Registry and comparison with other autoimmune-lymphoproliferative inborn errors of immunity.
Maccari ME, Wolkewitz M, Schwab C, et al.
The Journal of allergy and clinical immunology 2023; (152(4)):984-996.e10 doi:10.1016/j.jaci.2023.06.015.
PMID: 37390899 - 8
Clinical spectrum and features of activated phosphoinositide 3-kinase δ syndrome: A large patient cohort study.
Coulter TI, Chandra A, Bacon CM, et al.
The Journal of allergy and clinical immunology 2017; (139(2)):597-606.e4 doi:10.1016/j.jaci.2016.06.021.
PMID: 27555459 - 9
Case Report: EBV Chronic Infection and Lymphoproliferation in Four APDS Patients: The Challenge of Proper Characterization, Therapy, and Follow-Up.
Rivalta B, Amodio D, Milito C, et al.
Frontiers in pediatrics 2021; (9()):703853 doi:10.3389/fped.2021.703853.
PMID: 34540765 - 10
The Dark Side of Activated Phosphoinositide 3-Kinase-δ Syndrome 2: A Story Rewritten through FDG-PET.
Catelli A, Nanni C, Mulè R, et al.
Journal of clinical medicine 2024; (13(8)) doi:10.3390/jcm13082203.
PMID: 38673479 - 11
Disease Evolution and Response to Rapamycin in Activated Phosphoinositide 3-Kinase δ Syndrome: The European Society for Immunodeficiencies-Activated Phosphoinositide 3-Kinase δ Syndrome Registry.
Maccari ME, Abolhassani H, Aghamohammadi A, et al.
Frontiers in immunology 2018; (9()):543 doi:10.3389/fimmu.2018.00543.
PMID: 29599784 - 12
Evaluation of Lymphoproliferative Disease and Increased Risk of Lymphoma in Activated Phosphoinositide 3 Kinase Delta Syndrome: A Case Report With Discussion.
Pham MN, Cunningham-Rundles C
Frontiers in pediatrics 2018; (6()):402 doi:10.3389/fped.2018.00402.
PMID: 30619796 - 13
Activated phosphoinositide 3-kinase δ syndrome caused by PIK3CD mutations: expanding the phenotype.
Zhao P, Huang J, Fu H, et al.
Pediatric rheumatology online journal 2024; (22(1)):24 doi:10.1186/s12969-024-00955-7.
PMID: 38287413 - 14
Epstein-Barr Virus-Positive B-Cell Lymphoproliferative Disorder Complicated by Septic Shock in Activated PI3Kδ Syndrome: A Pediatric Case Report and Literature Review.
Zhao X, Ming X, Shang Z, et al.
Case reports in hematology 2026; (2026()):3644513 doi:10.1155/crh/3644513.
PMID: 42591980 - 15
[Activated phosphoinositide 3-kinase delta syndrome: report of seven cases].
Liu QH, Peng L, Huang H, et al.
Zhongguo dang dai er ke za zhi = Chinese journal of contemporary pediatrics 2024; (26(5)):499-505 doi:10.7499/j.issn.1008-8830.2312065.
PMID: 38802911 - 16
Case Report: Recurrent pulmonary infections with neck masses: a diagnostic challenge and literature review.
Zhao L, Zhao J, Lu Y
Frontiers in medicine 2026; (13()):1807946 doi:10.3389/fmed.2026.1807946.
PMID: 42040580
This APDS2 monitoring information is for educational purposes only and does not constitute medical advice. Your immunologist should tailor testing and fever instructions to your child or your specific situation; seek emergency care for severe symptoms.